eli lilly trials retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced. In Retatrutide Shows 28% Weight Loss
Description
It is especially relevant for patients taking or researching semaglutide, tirzepatide, GLP-1 injections, oral GLP-1 options, or physician-supervised weight loss programs
Honka H, Salehi M
Since then, research has continued, leading to newer, often more effective, and longer-acting versions
If oral semaglutide is covered by your insurance plan, out-of-pocket expenses may only include copays or coinsurance
You answer questions about your medical history, current medications, health goals, and body metrics like height and weight
